Tech Company Financing Transactions
Regado Biosciences Funding Round
On 3/27/2007, Regado Biosciences announced $23 million in Series C funding from Aurora Funds, Domain Associates and Quaker Partners.
Transaction Overview
Company Name
Announced On
3/27/2007
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series C
Investors
Proceeds Purpose
Regado's CEO Douglas Gooding said, "This financing will allow us to continue the clinical development of REG1 in multiple indications. Given the clinical validation that we have seen with the first program we will be investing some of this new capital in pipeline development as well."
Company Information
Company Status
Publicly-held
Industry
Biopharmaceutical
Mailing Address
701 Gateway Blvd. 300
San Francisco, CA 94080
USA
San Francisco, CA 94080
USA
Phone
Website
Email Address
Overview
Regado (NASDAQ: RGDO) is a spin-out of the Department of Surgery at Duke University Medical Center. Regado's technology enables the rational design of drug-antidote pairs against any target accessible to the bloodstream.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Laurent Fischer
Chief Financial Officer
Christopher Peetz
Chief Medical Officer
Eric Lefebvre
Chief Operating Officer
Helen Jenkins
Browse more venture capital transactions:
Prev: 3/26/2007: Wellpartner venture capital transaction
Next: 3/27/2007: Digital Fuel venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs